Esther Shohami

Prof. Esther Shohami


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Neurotherapeutics
Verified
Journal Article
Closed access
GUGali Umschweif
Gali Umschweif
SLSigal Liraz-Zaltsman
Sigal Liraz-Zaltsman
DSDalia Shabashov
Dalia Shabashov
AAAlexander Alexandrovich
Alexander Alexandrovich
VTVictoria Trembovler
Victoria Trembovler
ESEsther Shohami
Esther Shohami

1 March 2014 in Brain Research
Verified
Journal Article
Closed access
SDShlomit Dachir
Shlomit Dachir
DSDalia Shabashov
Dalia Shabashov
VTVictoria Trembovler
Victoria Trembovler
AAAlexander G. Alexandrovich
Alexander G. Alexandrovich
LBLarry I. Benowitz
Larry I. Benowitz
ESEsther Shohami
Esther Shohami

1 April 2021 in Experimental Neurology
Verified
Journal Article
Closed access
YFYael Friedman-Levi
Yael Friedman-Levi
SLSigal Liraz-Zaltsman
Sigal Liraz-Zaltsman
CSChen Shemesh
Chen Shemesh
KRKinneret Rosenblatt
Kinneret Rosenblatt
EKEfrat L. Kesner
Efrat L. Kesner
ESEsther Shohami
Esther Shohami

21 May 2014 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
GUGali Umschweif
Gali Umschweif
DSDalia Shabashov
Dalia Shabashov
AAAlexander G Alexandrovich
Alexander G Alexandrovich
VTVictoria Trembovler
Victoria Trembovler
MHMichal Horowitz
Michal Horowitz
ESEsther Shohami
Esther Shohami
Long-term exposure of mice to mild heat (34°C ± 1°C) confers neuroprotection against traumatic brain injury (TBI); however, the underling mechanisms are not fully understood. Heat acclimation (HA) increases hypothalamic angiotensin II receptor type 2 (AT2) expression and hypothalamic neurogenesis. Accumulating data suggest that activation of the brain AT2 receptor confers protection against several types of brain pathologies, including ischemia, a hallmark of the secondary injury occurring following TBI. As AT2 activates the same pro-survival pathways involved in HA-mediated neuroprotection (e.g., Akt phosphorylation, hypoxia-inducible factor 1α (HIF-1α), and brain-derived neurotrophic factor (BDNF)), we examined the role of AT2 in HA-mediated neuroprotection after TBI. Using an AT2-specific antagonist PD123319, we found that the improvements in motor and cognitive recovery as well as reduced lesion volume and neurogenesis seen in HA mice were all diminished by AT2 inhibition, whereas no significant alternations were observed in control mice. We also found that nerve growth factor/tropomyosin-related kinase receptor A (TrkA), BDNF/TrkB, and HIF-1α pathways are upregulated by HA and inhibited on PD123319 administration, suggesting that these pathways play a role in AT2 signaling in HA mice. In conclusion, AT2 is involved in HA-mediated neuroprotection, and AT2 activation may be protective and should be considered a novel drug target in the treatment of TBI patients.

27 February 2015 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
AMAniv Mann
Aniv Mann
RSReem Smoum
Reem Smoum
VTVictoria Trembovler
Victoria Trembovler
AAAlexander Alexandrovich
Alexander Alexandrovich
ABAviva Breuer
Aviva Breuer
ESEsther Shohami
Esther Shohami

10 December 2012 in Journal of Neurotrauma
Verified
Journal Article
Closed access
MPMaximilian Peters
Maximilian Peters
VTVictoria Trembovler
Victoria Trembovler
AAAlexander Alexandrovich
Alexander Alexandrovich
MPMoshe Parnas
Moshe Parnas
LBLutz Birnbaumer
Lutz Birnbaumer
ESEsther Shohami
Esther Shohami
Death of Central Nervous System (CNS) neurons following traumatic brain injury (TBI) is a complex process arising from a combination of factors, many of which are still unknown. It has been found that inhibition of transient receptor potential (TRP) channels constitutes an effective strategy for preventing death of CNS neurons following TBI. TRP channels are classified into seven related subfamilies, most of which are Ca2+ permeable and involved in many cellular functions, including neuronal cell death. We hypothesized that TRP channels of the TRPC subfamily may be involved in post-TBI pathophysiology and that the compound 5-isopropyl-2-methylphenol (carvacrol), by inhibition of TRP channels, may exert neuroprotective effect after TBI. To test these suppositions, carvacrol was given to mice after TBI and its effect on their functional recovery was followed for several weeks. Our results show that neurological recovery after TBI was significantly enhanced by application of carvacrol. To better define the type of the specific channel involved, the effect of carvacrol on the extent and speed of recovery after TBI was compared among mice lacking TRPC1, TRPC3, or TRPC5, relative to wild type controls. We found that neurological recovery after TBI was significantly enhanced by combining carvacrol with TRPC1 elimination, but not by the absence of TRPC3 or TRPC5, showing a synergistic effect between carvacrol application and TRPC1 elimination. We conclude that TRPC1-sensitive mechanisms are involved in TBI pathology, and that inhibition of this channel by carvacrol enhances recovery and should be considered for further studies in animal models and humans.